Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

About this trial

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly recognized cause of chronic liver disease and is closely linked with obesity, metabolic abnormalities, and nutritional status. Data on the frequency of MAFLD and its associated metabolic and nutritional factors in rural populations of Bangladesh are not up to date.

This study aims to determine the frequency of MAFLD and to evaluate its association with nutritional status and metabolic risk factors among adults in a rural population of Bangladesh. Eligible participants will undergo clinical assessment, anthropometric measurements, laboratory evaluation of metabolic parameters, and abdominal ultrasonography for the detection of hepatic steatosis. Nutritional status will be assessed using standard anthropometric and clinical criteria.

The findings of this study are expected to provide baseline epidemiological data on MAFLD in rural Bangladesh and to help identify associated metabolic and nutritional risk factors.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 years or above

Resident of the selected community

Disqualifiers

Pregnant women

Severe illness precluding participation like paralysis, bed ridden, cancer etc

Trial population

Place of study: Shimulia Union, Ashulia, Savar, Dhaka, Bangladesh Study Population: All adults of two villages of Shimulia Union who will give their consent to participate in the study

Trial design

Design model

Ecologic or community

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Frequency of MAFLD in a rural population of Bangladesh

Time frame
From December 2025 to October 2026

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.